Shanu Modi, MD


Dr. Modi on Trastuzumab Deruxtecan in HER2-low Breast Cancer

Shanu Modi, MD, discusses the significance of the FDA approval of the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-low breast cancer.

Karam Al-Issa, MD


Student Loan Debt, Immigration Status Often Drive Career Decisions for Fellows

Investigators from Indiana University decided to study some of the factors influencing career plans for physicians, focusing on current fellows and recent graduates of the hematology and medical oncology specialty in the United States.

Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College


Testing for PSMA in Community Settings

Scott T. Tagawa, MD, MS, FACP, discusses integration of prostate-specific membrane antigen [PSMA] positron emission tomography [PET] imaging into community practice to help identify potential candidates for PSMA-targeted radioligand therapy.

Amit Patel, BSc, MBBS, PhD, The Christie NHS Foundation Trust


Research on CAR T Therapy in Earlier Lines of Treatment

Amit Patel, BSc, MBBS, PhD, discusses currently ongoing clinical trials of CAR T-cell therapy in first- and second-line treatment settings and comments on potential developments on the horizon.

Evandro D. Bezerra, MD


Dr. Bezerra on Barriers to Enrollment for Clinical Trials in B-Cell NHL

Evandro D. Bezerra, MD, discusses barriers to enrollment in clinical trials for patients with aggressive B-cell non-Hodgkin lymphoma who have progressed on anti-CD19 CAR T-cell therapy.

James A. DeCaprio, MD


Dr. DeCaprio on Raising Awareness in Merkel Cell Carcinoma

James A. DeCaprio, MD, discusses raising awareness in Merkel cell carcinoma.

Inhye Ahn, MD


Dr. Ahn on Choosing Between Treatment Options in CLL

Inhye Ahn, MD, physician, discusses choosing between treatment options in chronic lymphocytic leukemia.

Uwe Platzbecker, MD


Summary of Unmet Needs and Future Directions in MDS

Experts close by summarizing key advances and remaining unmet needs across all MDS risk groups, and share their hopes for the future.

Aurélien Marabelle, MD, PhD


Dr. Marabelle on Preliminary Findings With SO-C101 in Advanced Solid Tumors

Aurélien Marabelle, MD, PhD, discusses preliminary findings from a trial examining SO-C101 in patients with advanced solid tumors.

Karim Chamie, MD


Dr. Chamie on Examining N-803 Plus BCG in BCG-Unresponsive NMIBC CIS

Karim Chamie, MD, discusses the design of the phase 2/3 QUILT-3.032 trial in patients with Bacillus Calmette-Guerín–unresponsive, non–muscle invasive bladder cancer carcinoma in situ.

Ulka N. Vaishampayan, MBBS, FAB


Dr. Vaishampayan on the Rationale of the PROBE Trial in RCC

Ulka Nitin Vaishampayan, MBBS, discusses the rationale of the phase 3 PROBE trial in advanced renal cell carcinoma.

Wen Wee Ma, MBBS


Dr. Ma on First-Line Treatment Considerations in Metastatic Pancreatic Cancer

Wen Wee Ma, MBBS, discusses first-line treatment considerations in metastatic pancreatic cancer.

Hannah Choe, MD


GvHD: Advice for Patients

Experts share their insights and advice on how to best communicate with patients who are actively dealing with acute or chronic GvHD.

Alexander E. Perl, MD, University of Pennsylvania


Future Treatment Landscape of AML

Corey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.

David Planchard, MD, PhD, Gustave Roussy Institute of Oncology


Dr. Planchard on the Benefit of Sunvozertinib in EGFR Exon 20–Mutated NSCLC

David Planchard, MD, PhD, discusses the benefit of sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer (NSCLC).

Michelle Melisko, MD


Evolving Treatment Landscape of HER2+ Metastatic Breast Cancer

Closing out their discussion on novel therapies for HER2+ metastatic breast cancer, experts share excitement for future clinical trials and strategies.

Gretchen G. Kimmick, MD, MS


Dr. Kimmick on Selecting Adjuvant Therapy for Patients With HER2+ Breast Cancer

Gretchen G. Kimmick, MD, MS, discusses selecting adjuvant therapy for patients with HER2-positive breast cancer.

Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute


ASH 2021: Updates in the Chronic Lymphocytic Leukemia Treatment Landscape

Following the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.

Jorge M. Mercado, MD


Dr. Mercado on Evolution of Biopsy Techniques in Lung Cancer

Jorge M. Mercado, MD, discusses the evolution of biopsy techniques in patients with lung cancer.

Chris Labaki, MD


Dr. Labaki on Disparities in Mammography Screenings During the COVID-19 Pandemic

Chris Labaki, MD, discusses racial disparities with regard to mammography screenings during the COVID-19 pandemic.

Elisabeth I. Heath, MD, FACP


Prostate Cancer Imaging: Unmet Needs and Knowledge Gaps

Medical oncologist Tian Zhang, MD, outlines the remaining unmet needs and knowledge gaps surrounding imaging of prostate cancer.

Nita Nair, MBBS, DNB, MCh


Dr. Nair on Using Yoga to Improve Quality of Life in Patients Undergoing Breast Cancer Treatments

Nita Nair, MBBS, DNB, MCh, discusses research evaluating the role of yoga as a way to improve the quality of life of patients undergoing breast cancer treatments.

Gregory P. Botta, MD, PhD


Dr. Botta on the Diagnosis and Treatment of ESCC

Gregory Botta, MD, PhD, discusses the diagnosis and treatment of patients with esophageal squamous cell carcinoma.

John Theurer Cancer Center, Hackensack University Medical Center


Groundbreaking Grant to John Theurer Cancer Center Will Establish the Hennessy Institute for Cancer Prevention and Applied Molecular Medicine

The family of Mike and Patti Hennessy made a transformational gift in their memory to establish the Hennessy Institute for Cancer Prevention and Applied Molecular Medicine.

Kyle Doherty


HRD-Directed Therapeutics Hold Potential in Breast Cancer, But Challenges Remain

Roadblocks such as PARP inhibitor resistance have resulted in an unmet need and uncertain optimal identification concerning patients who would elicit the most benefit from homologous recombination deficiency–directed therapies.

Jared Weiss, MD, University of North Carolina at Chapel Hill


Emerging Agents and Future of Small Cell Lung Cancer

Jared Weiss, MD, and Stephen V. Liu, MD discuss treatment of small cell lung cancer and therapies in the pipeline.

Brian Schulte, MD


Dr. Schulte on the PRECISION 1 Trial of Nab-Sirolimus in TSC1/2-Mutated Solid Tumors

Brian Schulte, MD, discusses the ongoing phase 2 PRECISION 1 basket trial evaluating the use of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring TSC1/2 mutations.

William Jacot, MD, PhD


Dr. Jacot on Ribociclib Dose Reduction in HR+/HER2– Advanced Breast Cancer

William Jacot, MD, PhD, discusses updated efficacy and safety results from the phase 2 AMALEE trial.

Bradley Corr, MD


Dr. Corr on the Utilization of Molecular Profiling in Endometrial Cancer

Bradley R. Corr, MD, discusses the utilization of molecular profiling in endometrial cancer.